STATE AND FEDERAL PHARMACY INTELLIGENCE RESOURCE

Blog

Feb
02

UPDATE: Naloxone and Opioid Antagonist Prescription Status in the States

by SAFPhIR Team

2015 was a record year for deaths linked to opioids. 33,000 deaths in one year. And the government has taken note. We’re already seeing unprecedented numbers of legislative and regulatory actions being taken at State and Federal levels with new laws regarding narcotic prescriptions.

Last March, the Obama Administration called for $1.1 billion in funding associated with opioid treatment. One of the proposed programs would allow states to purchase Naloxone, an opioid antagonist, to provide to first responders. This greatly impacts Naloxone distribution programs.

States have gotten the memo, too.

As of February 2, 20167, 44 States and the District of Columbia have regulations in place allowing Naloxone administration and opioid antagonist medications to be made available without requiring a prescription.

Curious which 6 states require prescriptions and which do not?

Last Update: February 2, 2017

Download SAFPhIR’s Report:     “Naloxone and Opioid Antagonist Prescription Status” 

If you are tracking this development and others that impact Managed Care Pharmacies in the U.S., SAFPhIR is for you.

SAFPhIR makes tracking the proliferation of federal and state laws and regulations easy. And, SAFPhIR subscribers get exclusive access to in-depth reports and analysis on the latest issues, including Opioids, Biosimilars and other hot topics. Our analysis informs your business decisions and makes it easy for your entire organization to not only be responsive to law and regulatory changes, but plan ahead for them. To schedule a demonstration of SAFPhIR’s subscription based service, contact us at info@safphir.com .

 

 

 

 

back

Login